Skip to content

Flatiron Health announces research to be presented at ISPOR 2024


April 2024

Flatiron Health announces research to be presented at ISPOR 2024

Advancing oncology research for precision medicine and equity in patient care 

Flatiron Health is pleased to announce their presence at ISPOR—The Professional Society for Health Economics and Outcomes Research 2024 Conference, set to take place May 5-8, 2024 in Atlanta. In addition to presenting seven research posters, Flatiron will lead a panel discussion and conduct a workshop, offering valuable insights and fostering collaboration within the healthcare community.

Flatiron’s contributions at ISPOR 2024 spotlight novel advancements in oncology real-world data, fueling the generation of fit for purpose real-world evidence. With this year's conference theme centering on health economics and outcomes research as a driving force for comprehensive health improvement, Flatiron is dedicated to contributing to this mission and improving and extending the lives of people with cancer. 

"Flatiron's participation at ISPOR 2024 reaffirms our dedication to pioneering oncology research, with studies ranging from targeted therapies in non-small cell lung cancer to inequities in endometrial cancer survival," said Javier Jimenez, Chief Medical Officer, Flatiron Health. "Our innovative methodologies highlight our efforts to push the boundaries of oncology research as we continue working to bridge the gap between care and research, benefiting people with cancer and the healthcare community."

Highlights of Flatiron’s presence at the conference include: 

  • A workshop on leveraging quantitative bias analysis for trust-worthy real-world evidence. 

  • A poster presentation on using machine learning to examine real-world response rates in clinical trial-aligned cohorts of patients with lung, colon, and breast cancer. 

  • A poster presentation that assesses the effectiveness of large language models to extract key PD-L1 details from electronic health records. 

Schedule a meeting with Flatiron Health at ISPOR US 2024, and learn more about our abstracts and events, including workshops and panels. 

Follow Flatiron Health on Twitter and LinkedIn for more updates from #ISPORAnnual and visit us in person at Booth #319.

Poster Presentations

Prevalence and incidence of ROS1 and NTRK rearrangements in real-world patients with advanced non-small cell lung cancer in the United States
Partners: Bristol-Myers Squibb, University of North Carolina at Chapel Hill, and University of Colorado Cancer Center 
Xinran Ma, Yichen Lu, Adam Lee, Cheryl Cho-Phan, I-Hsuan Su, Ying Zhang, Ross Camidge, John R Penrod, Yong Yuan
Code: EPH49
Date: Monday, May 6
Poster session time: 10:30AM-1:30PM

Racial and ethnic inequities in endometrial cancer survival from 2017 to 2022: assessing the influence of social determinants of health
Harlan Pittell, Cleo A. Ryals, Olive Mbah, Khilna Patel, Amy Pierre, Mustafa S. Ascha
Code: HPR9
Date: Monday, May 6
Poster session time: 10:30AM-1:30PM

Oncology practice setting classification in the US: considerations for real world evidence
Eric S. Meadows, Matthew Reynolds, Jenna Collins, Mark Guinter
Code: HSD9
Date: Monday, May 6
Poster session time: 10:30AM-1:30PM

Performance assessment of a disease-agnostic treatment sequencing heuristic for deriving line of therapy in a real-world, rare, multi-tumor cohort across tumor mutational burden status
Lilia Bouzit, Mounika Burugupalli, Tamara Snow, Brendan Kerr, Neyha Shankar, Kevin Andrus, Anosheh Afghahi, Cheryl Cho-Phan
Code: HSD42
Date: Monday, May 6
Poster session time: 3:30PM-6:30PM

Evaluating real-world response-based endpoint in the clinical trial settings among aNSCLC, mCRC and mBC patients
Cherie Zhang, Konstantin Krismer, Xiaoyan Wang, Christina Fullerton, Aaron Dolor, Niquelle Wade, Prakrit Baruah, Erica Yim, Tori Williams, Qianyu Yuan, Sam Wilkinson, Sheila Nemeth, Nisha Singh, Mengru Wang, Maddy Franco, Aaron Cohen, Erin Fidyk, Auriane Blarre, Kelly Magee
Code: MSR79
Date: Tuesday, May 7
Poster session time: 3:30PM-6:30PM

Assessing the potential value of the Flatiron Health commercial mortality data combined with publicly available death data for non-oncology research
Matthew W Reynolds, Jenna M Collins, Eric Meadows, Qianyi Zhang, Aaron Dolor, Niquelle Brown Wadé, Raina Mathur, Emily Castellanos
Code: RWD141
Date: Tuesday, May 7
Poster session time: 3:30PM-6:30PM

Using large language models to extract PD-L1 testing details from electronic health records
Aaron Cohen, Michael Waskom, Blythe Adamson, Jack Kelly, Guy Amster
Code: MSR64
Date: Tuesday, May 7
Poster session time: 3:30PM-6:30PM

About Flatiron Health

Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.

Media Contact

Nina Toor